After Divestiture, FTC To Allow Drug Acquistion

Law360, New York (April 17, 2007, 12:00 AM EDT) -- The U.S. Federal Trade Commission has given the green light to Actavis Group’s acquisition of Abrika Pharmaceuticals, Inc., but only if the companies sell the rights to a blood pressure drug.

The regulator said Monday that the deal as proposed would have created a monopoly in the U.S. for generic isradipine capsules. The drug is typically prescribed to patients to lower their blood pressure, and is also used to treat hypertension, ischemia, and depression.

The companies agreed to divest all the rights and assets to make...
To view the full article, register now.